OSMOTICA PHARM Revenue 2017-2021 | OSMT

OSMOTICA PHARM revenue from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
OSMOTICA PHARM Annual Revenue
(Millions of US $)
2020 $178
2019 $240
2018 $264
2017 $246
2016 $218
OSMOTICA PHARM Quarterly Revenue
(Millions of US $)
2021-06-30 $12
2021-03-31 $24
2020-12-31 $72
2020-09-30 $57
2020-06-30 $0
2020-03-31 $49
2019-12-31 $60
2019-09-30 $65
2019-06-30 $58
2019-03-31 $57
2018-12-31 $66
2018-09-30 $66
2018-06-30 $72
2018-03-31 $60
2017-12-31
2017-09-30 $54
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.121B $0.178B
Osmotica Pharmaceuticals Public Limited Company operates as a biopharmaceutical company. It offers tablets, dietary supplements and drugs for the treatment of women's health. The company's product pipeline consists of Methylphenidate HCl ER 72 mg Tablets, Osmolex ER(TM), Lorzone(R), ConZip(R), Divigel(R) and OB Complete(R). Its delivery system includes Osmodex(R) drug delivery system. Osmotica Pharmaceuticals Public Limited Company is based in Bridgewater, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00